Related Experiment Videos
Circulating TGF-beta1 does not cross the intact blood-brain barrier
Abba J Kastin1, Victoria Akerstrom, Weihong Pan
1VA Medical Center and Tulane University School of Medicine, New Orleans, LA 70112-1262, USA. peptides@tulane.edu
Journal of Molecular Neuroscience : MN
|September 23, 2003
Summary
Transforming growth factor-beta (TGF-beta) does not readily cross the intact blood-brain barrier (BBB) after intravenous injection. Its therapeutic potential may be limited to conditions with a compromised BBB.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Transforming growth factor-beta (TGF-beta) exhibits neuroprotective properties.
- TGF-beta can cross a disrupted blood-brain barrier (BBB).
- The ability of TGF-beta to cross an intact BBB is not well understood.
Purpose of the Study:
- To quantify the permeation of TGF-beta across the normal mouse BBB.
- To assess the therapeutic potential of systemically administered TGF-beta for brain conditions.
Main Methods:
- Intravenous injection of TGF-beta1 in mice.
- Quantification of TGF-beta1 levels using high-performance liquid chromatography.
- Comparison with a vascular marker (99mTc-albumin).
- Assessment of lipophilicity and hydrogen bonding potential.
Main Results:
- TGF-beta1 is stable in circulating blood.
- TGF-beta1 does not significantly cross the intact BBB.
- Permeation rate is comparable to the vascular marker 99mTc-albumin.
- High hydrogen bonding potential correlates with poor BBB penetration.
Conclusions:
- Systemic administration of TGF-beta1 has limited efficacy for the intact BBB.
- TGF-beta1's therapeutic application is likely restricted to conditions with BBB disruption.
- Further research may explore targeted delivery methods for TGF-beta1 to the brain.